Berenson, James R <br/><br/>
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2009 
 - 1069-75 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-08-1261  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Combined Modality Therapy<br/>Drug Administration Schedule<br/>Ethylenediamines--administration & dosage<br/>Humans<br/>Maximum Tolerated Dose<br/>Multiple Myeloma--therapy<br/>Organophosphonates--administration & dosage<br/>Platelet Count<br/>Pyrazines--administration & dosage<br/>Radioisotopes--administration & dosage<br/>Recurrence<br/>Samarium--administration & dosage